Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death

Neuronal influences are necessary to produce mitochondrial co-localization with glutamate transporters in astrocytes

(2014) Christopher I. Ugbode et al.   JOURNAL OF NEUROCHEMISTRY

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

(2013) T. M. Herndon et al.   CLINICAL CANCER RESEARCH

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

(2013) Meletios Dimopoulos et al.   LANCET ONCOLOGY

Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors

(2013) T Hideshima et al.   LEUKEMIA

The role of endoplasmic reticulum stress in maintaining and targeting multiple myeloma: a double-edged sword of adaptation and apoptosis

(2013) Shai White-Gilbertson et al.   Frontiers in Genetics

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Proteasome inhibitors in multiple myeloma: 10 years later

(2012) P. Moreau et al.   BLOOD

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy

(2012) Y. Zang et al.   CLINICAL CANCER RESEARCH

Transient Aggregation of Ubiquitinated Proteins Is a Cytosolic Unfolded Protein Response to Inflammation and Endoplasmic Reticulum Stress

(2012) Xian-De Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Compromising the Unfolded Protein Response Induces Autophagy-Mediated Cell Death in Multiple Myeloma Cells

(2011) Anne-Sophie Michallet et al.   PLoS One

Proteasome and HDAC: who's zooming who?

(2010) D. McConkey   BLOOD

HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy

(2010) Joo-Yong Lee et al.   EMBO JOURNAL

Fighting disease by selective autophagy of aggregate-prone proteins

(2010) Helene Knaevelsrud et al.   FEBS LETTERS

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition

(2010) L Santo et al.   ONCOGENE

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

(2009) F. Parlati et al.   BLOOD

Inhibition of eIF2α Dephosphorylation Maximizes Bortezomib Efficiency and Eliminates Quiescent Multiple Myeloma Cells Surviving Proteasome Inhibitor Therapy

(2009) Denis M. Schewe et al.   CANCER RESEARCH

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

(2009) N Raje et al.   LEUKEMIA

Effect of autophagy on multiple myeloma cell viability

(2009) B. Hoang et al.   MOLECULAR CANCER THERAPEUTICS

Role of the Aggresome Pathway in Cancer: Targeting Histone Deacetylase 6-Dependent Protein Degradation

(2008) A. Rodriguez-Gonzalez et al.   CANCER RESEARCH

The aggresome pathway as a target for therapy in hematologic malignancies

(2008) Tiffany Simms-Waldrip et al.   MOLECULAR GENETICS AND METABOLISM

Autophagy fights disease through cellular self-digestion

(2008) Noboru Mizushima et al.   NATURE

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE